Skip to main content
. 2022 Mar 20;2022:3080263. doi: 10.1155/2022/3080263

Figure 5.

Figure 5

Rosiglitazone (ROSI) protects hair cells from cisplatin toxicity by decreasing lipid peroxidation levels. (a) HEI-OC1 cells treated with varying concentrations of ROSI for 24 h were analyzed by Cell Counting Kit-8 (CCK-8). (b) The relative MDA content levels in HEI-OC1 cells with cisplatin (20 μM for 24 h) exposure, with or without ROSI (0.5 μM for 24 h) pretreatment. (c and d) Fluorescence images displaying 4-HNE immunostaining and the relative fluorescence intensity of 4-HNE. (e) Representative images of C11-BODIPY (581/591) staining in different groups of cells. (f) Representative images of cochlear explants stained with phalloidin in cisplatin (50 μM for 30 h) exposure, with or without ROSI (30 μM for 24 h) treatment (scale bar, 20 μm). (g) The relative MDA content levels in different groups of cochlear explants. (h and i) Hair cell counts and quantification obtained from zebrafish in cisplatin (400 mM for 6 h) exposure with or without ROSI (40 mM for 6 h) treatment (scale bar, 20 μm). (The data were all quantified by ImageJ software. n = 3 individual experiments. The data are shown as mean ± SEM. ###p < 0.001 and ####p < 0.0001 vs the control group. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 vs the cisplatin group. NC: control group treated with same dose of DMF and DMSO in other groups. MDA: malondialdehyde. 4-HNE: 4-hydroxynonenal. R-BODIPY: reduced BODIPY. O-BODIPY: oxidized BODIPY. Apex: apical turn of cochlear base membrane. Middle: middle turn of cochlear base membrane. Base: base turn of cochlear base membrane.).